Cite
MLA Citation
J. Kaplan et al.. “TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY.” Hematological oncology, vol. 35, n.d., pp. 72–74. http://access.bl.uk/ark:/81055/vdc_100047420017.0x000032